modernretina.com

Sivuston tiedot modernretina.com

Modern Retina – Ophthalmology News, Events & Expert Insights

 Luotu Maaliskuu 31 2026 15:12 PM

Vanhentuneet tiedot? PÄIVITÄ !

Pisteet 57/100

SEO Sisältö

Otsikko

Modern Retina – Ophthalmology News, Events & Expert Insights

Pituus : 60

Täydellistä, otsikkosi sisältää väliltä 10 ja 70 kirjainta.

Kuvaus

Modern Retina provides ophthalmology professionals with the latest advancements, research, and expert insights in retinal care to improve patient outcomes.

Pituus : 155

Hienoa, sinun meta-kuvauksesi sisältää väliltä70 ja 160 kirjainta.

Avainsanat

Erittäin huono. Emme löytäneen meta -sanoja sivultasi. Käytä Tätä ilmaista meta-kuvaus generaattoria lisätäksesi kuvauksen.

Open Graph (OG-tägit) tarjoavat mahdollisuuden merkitä verkkosivustojen sisältöä meta-tiedoilla.

Hienoa, sinun sivu käyttää hyödyksi Open Graph protokollaa (OG meta prop).

Omaisuus Sisältö
title Modern Retina
type website
image https://www.modernretina.com/MR_Hover_Logo.jpg
url https://www.modernretina.com/
image:url https://www.modernretina.com/MR_Hover_Logo.jpg
image:width 1200
image:height 630
image:alt Modern Retina – Ophthalmology News, Events & Expert Insights

Otsikot

H1 H2 H3 H4 H5 H6
1 56 46 4 16 0
  • [H1] Latest News
  • [H2] Conference Coverage
  • [H2] Trending on Modern Retina
  • [H2] Shorts
  • [H2] Podcasts
  • [H2] Videos
  • [H2] Modern Retina Digital Edition
  • [H2] Continuing Medical Education
  • [H2] (CME Track) Revolutionizing nAMD and DME Management: Collaborative Strategies in the Age of Durable Treatments
  • [H2] (CME Track) Expanding Horizons in Toric IOLs: Translating Technological Advances Into Improved Patient Outcomes
  • [H2] (CME Track) The Neural Frontier: Mapping Neurostimulation Across the DED Patient Spectrum for Refractive Surgery
  • [H2] (COPE Credit) Time Matters in GA: The Impact of Early Detection and Proactive Treatment Approaches
  • [H2] (CME Track) Visionary Approaches: Rethinking Therapeutic and Interventional Glaucoma Management
  • [H2] (CME Credit) Time Matters in GA: The Impact of Early Detection and Proactive Treatment Approaches
  • [H2] (CME Track) The TED Perspective: A Multidisciplinary Approach to Thyroid Eye Care
  • [H2] (COPE Track) Patient-Centered Treatment Strategies in the Management of nAMD and DME
  • [H2] (CME Track) Patient-Centered Treatment Strategies in the Management of nAMD and DME
  • [H2] Practical Approaches to Modern Dry Eye Treatment and Management
  • [H2] (COPE Track) Visionary Approaches: Rethinking Therapeutic and Interventional Glaucoma Management
  • [H2] (COPE Track) Revolutionizing nAMD and DME Management: Collaborative Strategies in the Age of Durable Treatments
  • [H2] (COPE Track) Expanding Horizons in Toric IOLs: Translating Technological Advances Into Improved Patient Outcomes
  • [H2] (COPE Track) The TED Perspective: A Multidisciplinary Approach to Thyroid Eye Care
  • [H2] (COPE Track) The Neural Frontier: Mapping Neurostimulation Across the DED Patient Spectrum for Refractive Surgery
  • [H2] 20th Annual Controversies in Modern Eye Care
  • [H2] (CME Track) Clinical Consultations™: Framing a New Approach to Geographic Atrophy Management – Expert Insights into Recent Developments
  • [H2] (COPE Track) Clinical Consultations™: Framing a New Approach to Geographic Atrophy Management – Expert Insights into Recent Developments
  • [H2] (CME Track) Rapid Reviews in Retina™: Emerging Updates from Winter 2025 – Addressing the Wealth of New Data in Treatments for nAMD and DME
  • [H2] (COPE Track) Rapid Reviews in Retina™: Emerging Updates from Winter 2025 – Addressing the Wealth of New Data in Treatments for nAMD and DME
  • [H2] Living With X-Linked Retinitis Pigmentosa: What We Can Learn From a Patient’s Experience
  • [H2] (CME Track) Collaborative Community Connections™: Mastering the Management of nAMD and DME Through Therapeutic Innovation
  • [H2] Living With X-Linked Retinitis Pigmentosa: What We Can Learn From a Patient’s Experience
  • [H2] (COPE Track) Collaborative Community Connections™: Mastering the Management of nAMD and DME Through Therapeutic Innovation
  • [H2] Collaborative Care Symposium
  • [H2] Navigating the Glaucoma Therapeutic and Surgical Landscape: From Conventional to Cutting-Edge
  • [H2] (CME Track) Neurotrophic Keratitis: Multidisciplinary Approaches to Enhance Patient Outcomes
  • [H2] (COPE Track) Neurotrophic Keratitis: Multidisciplinary Approaches to Enhance Patient Outcomes
  • [H2] (CME Track) The Neural Network: Exploring The Role of Neuromodulation in Dry Eye Disease Management
  • [H2] (COPE Track) The Neural Network: Exploring The Role of Neuromodulation in Dry Eye Disease Management
  • [H2] (CME Track) Toric IOLs Unleashed: From Technological Progress to Patient Success
  • [H2] (COPE Track) Clinical Case Connections: Understanding the Impact of Advances in Treatment for DME and DR
  • [H2] (COPE Track) Toric IOLs Unleashed: From Technological Progress to Patient Success
  • [H2] (COPE Track) Clinical Case Connections: Expert Insights on Applying Therapeutic Innovations in nAMD
  • [H2] (CME Track) Clinical Case Connections: Expert Insights on Applying Therapeutic Innovations in nAMD
  • [H2] (CME Track) Clinical Case Connections: Understanding the Impact of Advances in Treatment for DME and DR
  • [H2] Neurotrophic Keratitis Insights: An Interactive Corneal Sensitivity Testing Workshop
  • [H2] (COPE Credit) Navigating Pharmacological Presbyopia Treatment for Enhanced Patient Care
  • [H2] (COPE Track) Small Mites, Big Impact: Revolutionizing Demodex Blepharitis Care
  • [H2] (CME Credit) Navigating Pharmacological Presbyopia Treatment for Enhanced Patient Care
  • [H2] (CME Track) Small Mites, Big Impact: Revolutionizing Demodex Blepharitis Care
  • [H2] Rapid Reviews in Retina™: Emerging Updates from Spring 2025—Addressing the Wealth of New Data in Treatments for Neovascular Retinal Disease
  • [H2] Interventional Dry Eye: A Stepwise Treatment & Management Approach
  • [H2] (CME Track) Rapid Reviews in Retina™: Emerging Updates from Summer 2025—Addressing the Wealth of New Data in Treatments for Neovascular Retinal Disease
  • [H2] (CME Track) A Forward Look at Anti-VEGF Therapies: A Paradigm Shift in Neovascular Retinal Disease Management
  • [H2] (CME Track) Community Collaborative Connections™: Optimizing the Collaborative Care of Neovascular Retinal Disease in a New Age of Treatment
  • [H2] (CME Track) The Evolution of MacTel Management: Integrating Neuroprotective Therapies Into Clinical Practice
  • [H2] (CME Track) Collaborating Across the Continuum™: Best Practices in Patient-Centric Team Management of XLRP
  • [H2] All News
  • [H3] Aflibercept to treat ROP in extremely-low-birth-weight children
  • [H3] Multi-luminance shape discrimination test shows reliability in low-vision RP population
  • [H3] Aflibercept to treat ROP in extremely-low-birth-weight children
  • [H3] Eichenbaum Acorns: Collaborative retina care with Jeffry D. Gerson, OD, FAAO
  • [H3] Eichenbaum Acorns: Mentorship, momentum, and the making of a retina podcast
  • [H3] Eichenbaum Acorns: Inside the mindset of an early adopter with Jordan M. Graff, MD, FACS
  • [H3] The Retina TL;DR: Redefining office-based surgery for retina care with Jonathan Feistmann, MD
  • [H3] Eichenbaum Acorns: A leadership conversation with Rishi P. Singh, MD, FASRS, on advancing CME
  • [H3] The Retina TL;DR: Rethinking retinal detachment repair with Tony Stefater, MD, PhD; and Tommy Stryjewski, MD
  • [H3] PHOTON Trial Outcomes: Impact on DME Patient Care in Clinical Practice
  • [H3] PULSAR Study Findings: Implications for Treating nAMD in Clinical Practice
  • [H3] Integrating AI to manage DR in a primary care setting
  • [H3] What to expect from virtual AAO 2020
  • [H3] Genetic Retinoblastoma Risk Stratified by Age Among Patients with Metachronous Bilateral Conversion
  • [H3] Galimedix Therapeutics earns milestone payment in ophthalmology partnership with Théa Open Innovation
  • [H3] Ophthalmic drug shortages more frequent, longer lasting than average
  • [H3] Johnson & Johnson’s TECNIS PureSee EDOF IOL cleared for US market
  • [H3] Eichenbaum Acorns: Collaborative retina care with Jeffry D. Gerson, OD, FAAO
  • [H3] NovaBridge, Visara report positive phase 2a results for dual VEGF-A/ANG-2 inhibitor VIS-101
  • [H3] FDA clears phase I/II trial of SVT-001 cell therapy for familial drusen–associated vision loss
  • [H3] Ocugen completes enrollment in liMeliGhT phase 3 trial of OCU400 for retinitis pigmentosa
  • [H3] Pegcetacoplan Does Not Impact Anti-VEGF Treatment in Geographic Atrophy, With Ted Leng, MD, MS
  • [H3] Q&A: AI-predicted retinal function shows promise in geographic atrophy
  • [H3] Dr. Mali’s top 5 predictions in ophthalmology for 2026
  • [H3] The Retina TL;DR with Dr. Weng: Tracking retinal gene therapies with Arshad M. Khanani, MD, MA, FASRS
  • [H3] Q&A: Gennady Landa, MD, shares clinical insights on the ranibizumab ocular implant
  • [H3] Samsung Bioepis reaches settlement agreement for Eylea (aflibercept) biosimilar
  • [H3] ISS 2026 highlights advances in ophthalmic imaging for retinal practice
  • [H3] American College of Physicians policy paper urges medical community to drop the term “'provider"
  • [H3] PRIMA System: A major step in the battle against GA
  • [H3] MeiraGTx Licenses complement-targeted geographic atrophy program from ZipBio
  • [H3] Metformin use associated with reduced incidence of intermediate AMD
  • [H3] FDA decision: Carbachol–brimonidine ophthalmic solution approved for presbyopia following BRIO phase 3 results
  • [H3] New optoretinography technique allows direct measurement of rod function in vivo
  • [H3] Navigating geographic atrophy from biomarkers to bilateral therapy
  • [H3] Ollin Biosciences reports positive head-to-head phase 1b data for OLN324 vs faricimab
  • [H3] Eichenbaum Acorns: Mentorship, momentum, and the making of a retina podcast
  • [H3] Long-lived Greenland sharks may point to new approaches for retinal disease
  • [H3] Molecular insights and clinical experience: Extending anti-VEGF durability
  • [H3] Q&A: Evolving approaches to geographic atrophy management
  • [H3] Nanoscope secures new US patent for Multi-Characteristic Opsin (MCO) technology platform
  • [H3] Rates of retinal layer thinning predict visual field progression in glaucoma
  • [H3] First patient treated in dose-expansion portion of SpliceBio's phase 1/2 ASTRA clinical trial
  • [H3] FDA grants Fast Track Designation to Complement Therapeutics’ CTx001 for geographic atrophy
  • [H3] 8 things to know about aflibercept 8 mg for retinal vascular disease
  • [H3] A new treatment round-up for AMD and GA
  • [H4] Multi-luminance shape discrimination test shows reliability in low-vision RP population
  • [H4] Phase 2 topline data: Ocugen OCU410 reduces geographic atrophy lesion growth by 31% at 12 months
  • [H4] The Retina TL;DR with Dr. Weng: Moving beyond anti-VEGF with OTX-TKI and Pravin U. Dugel, MD
  • [H4] ONL Therapeutics randomizes first European patient in phase 2 GA trial of Xelafaslatide
  • [H5] The Retina TL;DR with Dr. Weng: Moving beyond anti-VEGF with OTX-TKI and Pravin U. Dugel, MD
  • [H5] Pegcetacoplan Does Not Impact Anti-VEGF Treatment in Geographic Atrophy, With Ted Leng, MD, MS
  • [H5] The Retina TL;DR with Dr. Weng: Tracking retinal gene therapies with Arshad M. Khanani, MD, MA, FASRS
  • [H5] Exploring Emerging Therapies in the Retinal Vascular Disease Pipeline
  • [H5] The Retina TL;DR with Dr. Weng: Targeting the Fas signaling pathway with David Zacks, MD, PhD
  • [H5] Evaluating Safety and Clinical Confidence between Aflibercept 8 mg and 2 mg in Retinal Vascular Diseases
  • [H5] Management Approaches for Suboptimal Responders in AMD, DME, and RVO
  • [H5] Comparing Aflibercept 8 mg and Faricimab in RVO
  • [H5] Insights from Privotal Trials for Aflibercept (8 mg) in RVO
  • [H5] Evaluating Retinal Drying, Durability and IOP Management with Second-Generation Anti-VEGF Therapies in Retinal Vascular Diseases
  • [H5] Loading Dose Adjustments and Treatment Switching Strategies in Retinal Vascular Diseases
  • [H5] Enhancing Durability and Fluid Control with Aflibercept 8 mg in Retinal Vascular Diseases
  • [H5] Evolving Therapeutic Strategies with Next-Generation Anti-VEGF Agents in Retinal Vascular Diseases
  • [H5] Clinical Insights Shaping Real-World Decision-Making in Geographic Atrophy
  • [H5] Managing Geographic Atrophy in a 90-Year-Old Patient with Coexisting Neovascular AMD and Recurrent CNV Activation
  • [H5] Evaluating Progressive Multifocal Geographic Atrophy in an Asymptomatic 81-Year-Old Male

Kuvat

Emme löytäneet 135 yhtään kuvia tältä sivustolta.

23 Alt-attribuutit on tyhjiä tai poistettu. Lisää vaihtoehtoista tekstiä niin, että hakukoneet ymmärtävät paremmin kuvatesi sisällön.

Kirjain/HTML suhde

Suhde : 3%

Tämän sivun / sivujen suhde teksti -> HTML on vähemmäinkuin 15 prosenttia, tämä tarkoittaa sitä, että luultavasti tulee tarvitsemaan lisää teksti sisältöä.

Flash

Täydellistä!, Flash-sisältöä ei ole havaittu tällä sivulla.

html-dokumentti sivun sisälle (Iframe)

Hienoa, Tällä sivulla ei ole Iframeja.

URL- Uudelleenkirjoitus

Hyvä. Sinun linkkisi näyttävät puhtailta!

Alleviivaa URL-osoitteet

Täydellistä! URL-osoitteissasi ei ole merkintöjä.

Sivun linkit

Löysimme yhteensä 89 linkit jotka sisältää 0 linkit tiedostoihin

Ankkuri Tyyppi Mehu
All News Sisäinen Antaa mehua
Blogs Sisäinen Antaa mehua
All Videos Sisäinen Antaa mehua
Case-Based Roundtable Series Sisäinen Antaa mehua
Eichenbaum Acorns Sisäinen Antaa mehua
Expert Interviews Sisäinen Antaa mehua
Eyeviews Sisäinen Antaa mehua
Insights Sisäinen Antaa mehua
Medical World News Ulkoinen Antaa mehua
Podcasts Sisäinen Antaa mehua
Rapid Readouts Sisäinen Antaa mehua
The Retina TL;DR Sisäinen Antaa mehua
Viewpoints Sisäinen Antaa mehua
Conference Coverage Sisäinen Antaa mehua
Conference Listing Sisäinen Antaa mehua
Modern Retina Digital Edition Sisäinen Antaa mehua
Supplements And Featured Publications Sisäinen Antaa mehua
Between the Lines Sisäinen Antaa mehua
CME/CE Sisäinen Antaa mehua
EYLEA 8mg for nAMD and DME Treatment Sisäinen Antaa mehua
Sponsored Resources Sisäinen Antaa mehua
Partners Sisäinen Antaa mehua
Subscribe Sisäinen Antaa mehua
AMD Sisäinen Antaa mehua
Wet AMD Sisäinen Antaa mehua
Biosimilar Sisäinen Antaa mehua
Diabetic Macular Edema Sisäinen Antaa mehua
Diabetic Eye Awareness Sisäinen Antaa mehua
Diabetic Retinopathy Sisäinen Antaa mehua
Geographic Atrophy Sisäinen Antaa mehua
Imaging Sisäinen Antaa mehua
Inherited Retinal Diseases Sisäinen Antaa mehua
Ophthalmology Sisäinen Antaa mehua
RVO Sisäinen Antaa mehua
Retina Technology Sisäinen Antaa mehua
Retinal Surgery Sisäinen Antaa mehua
Uveitis Sisäinen Antaa mehua
Geographic Atrophy Sisäinen Antaa mehua
ISS 2026 highlights advances in ophthalmic imaging for retinal practice Sisäinen Antaa mehua
FLORetina: Inadvertent anti-VEGF interval increases during the COVID-19 pandemic Sisäinen Antaa mehua
Treating MacTel: First identify patient candidates and appropriate eye selection Sisäinen Antaa mehua
A medical fellow finds some magic at the AAO Annual Meeting Sisäinen Antaa mehua
FLORetina 2025: EU-ROP Registry bridges borders for real-world insight Sisäinen Antaa mehua
FLORetina 2025: Updates on tinlarebant in adolescent Stargardt disease Sisäinen Antaa mehua
FLORetina 2025: Long-term follow-up in pediatric gene therapy Sisäinen Antaa mehua
FLORetina 2025: Mary Elizabeth Hartnett on ROP research and risk management Sisäinen Antaa mehua
FLORetina 2025: Reframing retinal disease through the lens of choroidal health Sisäinen Antaa mehua
FLORetina 2025: Antithrombotic use examined in wet AMD submacular hemorrhage Sisäinen Antaa mehua
Martin David Harp Sisäinen Antaa mehua
Christina Y. Weng, MD, MBA, FASRS Sisäinen Antaa mehua
View All Sisäinen Antaa mehua
Eichenbaum Acorns: Collaborative retina care with Jeffry D. Gerson, OD, FAAO Sisäinen Antaa mehua
Eichenbaum Acorns: Mentorship, momentum, and the making of a retina podcast Sisäinen Antaa mehua
Eichenbaum Acorns: Inside the mindset of an early adopter with Jordan M. Graff, MD, FACS Sisäinen Antaa mehua
The Retina TL;DR: Redefining office-based surgery for retina care with Jonathan Feistmann, MD Sisäinen Antaa mehua
Eichenbaum Acorns: A leadership conversation with Rishi P. Singh, MD, FASRS, on advancing CME Sisäinen Antaa mehua
The Retina TL;DR: Rethinking retinal detachment repair with Tony Stefater, MD, PhD; and Tommy Stryjewski, MD Sisäinen Antaa mehua
PHOTON Trial Outcomes: Impact on DME Patient Care in Clinical Practice Sisäinen Antaa mehua
PULSAR Study Findings: Implications for Treating nAMD in Clinical Practice Sisäinen Antaa mehua
Integrating AI to manage DR in a primary care setting Sisäinen Antaa mehua
What to expect from virtual AAO 2020 Sisäinen Antaa mehua
View More Sisäinen Antaa mehua
Navigating geographic atrophy from biomarkers to bilateral therapy Sisäinen Antaa mehua
8 things to know about aflibercept 8 mg for retinal vascular disease Sisäinen Antaa mehua
Inside the mindset of an early adopter Sisäinen Antaa mehua
Challenges for young physicians treating patients with GA Sisäinen Antaa mehua
AAO highlight: Looking ahead to 2026 Sisäinen Antaa mehua
How AI is reshaping ophthalmology in 2025 and beyond Sisäinen Antaa mehua
Seeing the difference: Multimodal imaging for AMD and GA Sisäinen Antaa mehua
Ryan Livingston Sisäinen Antaa mehua
Lynda Charters Sisäinen Antaa mehua
Kevin Kunzmann Sisäinen Antaa mehua
Jeffry D. Gerson, OD, FAAO Sisäinen Antaa mehua
Theodore Leng, MD, MS Sisäinen Antaa mehua
Sheryl Stevenson Sisäinen Antaa mehua
Joshua Mali, MD Sisäinen Antaa mehua
Arshad M. Khanani, MD, MA, FASRS Sisäinen Antaa mehua
Modern Retina Staff Reports Sisäinen Antaa mehua
Jayanth Sridhar, MD Sisäinen Antaa mehua
Matt Hoffman Sisäinen Antaa mehua
Sheila Setork, OD Sisäinen Antaa mehua
About Sisäinen Antaa mehua
Advertise Sisäinen Antaa mehua
Editorial Sisäinen Antaa mehua
Contact Us Sisäinen Antaa mehua
Terms and Conditions Sisäinen Antaa mehua
Privacy Sisäinen Antaa mehua
Do Not Sell My Personal Information Ulkoinen Antaa mehua
Home Sisäinen Antaa mehua

SEO avainsanat

Avainsana pilvi

cme fasrs more view retinal management video cope track faao

Avainsanojen johdonmukaisuus

Avainsana Sisältö Otsikko Avainsanat Kuvaus Otsikot
more 64
view 52
video 44
track 35
faao 24

Käytettävyys

Url

Sivusto : modernretina.com

Pituus : 16

Pikkukuva (favicon)

Hienoa, sinun sivulla on favicon (pikakuvake).

Tulostettavuus

Emme löytäneet tulostusystävällistä CSS-palvelua.

Kieli

Hyvä. Ilmoitettu kieli on en.

Metatietosanastostandardi informaatio (DC)

Tämä sivu ei käytä hyödyksi (DublinCore =DC) metatietosanastostandardi informaatiokuvausta.

Dokumentti

(dokumenttityyppi); Merkistökoodaus

HTML 5

Koodaus/tietojenkäsittely

Täydellistä. Ilmoitettu asiakirjan merkkijono on UTF-8.

W3C Voimassaolo

Virheet : 0

Varoitukset : 0

Sähköpostin yksityisyys

Varoitus! Ainakin yksi sähköpostiosoite on löytynyt tavallisesta tekstistä. Käytä tätä ilmaista antispam suojausta piilottaaksesi sähköpostiosoitteet spämmereiltä.

HTML Epäonnistui

Hienoa! Emme ole löytäneet vanhentuneita HTML-tunnisteita HTML-koodistasi.

Nopeus neuvot

Erinomaista, verkkosivustosi ei käytä sisäkkäisiä taulukoita.
Harmillista, Sivustosi käyttää sisäisiä tyylejä.
Hienoa, Sivustossasi on muutamia CSS-tiedostoja.
Harmillista, sivustossasi on liikaa JavaScript-tiedostoja (enemmänkuin6).
Täydellistä, Sivustosi hyödyntää gzipia.

Mobiili

Mobiili optimointi

Apple-kuvake
Meta Viewport -tunniste
Flash sisältö

Optimoi

XML Sivukartta

Hienoa, sivustossasi on XML-sivukartta.

https://www.modernretina.com/sitemap.xml
https://www.modernretina.com/sitemap-news.xml

Robots.txt

https://modernretina.com/robots.txt

Hienoa, sivustossasi on robots.txt-tiedosto.

Analyysit

Hienoa, sivustossasi on analyysityökalu.

   Google Analytics

Sivuston nopeus

Laite
Luokat

Free SEO Testing Tool

Free SEO Testing Tool On ilmainen SEO työkalu, joka auttaa sinua analysoimaan Web-sivusi